Two South Korean biotechnology firms are expected to receive government approval for their stem cell drugs this month, paving the way for the world’s second batch of stem cell-based medicines to hit the market, sources said Sunday.
The Korea Food and Drug Administration (KFDA) will likely approve “Cartistem” produced by Medipost Inc. for treatment of damaged cartilage in mid-January, they said. A stem cell-based anal fistula drug by Anterogen Co. will also receive official permission within this month.
“We are currently reviewing documents additionally submitted by each company. Permission will be issued sooner or later,” a KFDA official said on condition of anonymity.
For full article see Korea Times.